Primary contact

A spin-off from the University of Porto, Immunethep is a biotech startup company developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. Its first product, PNV1 - Paragon Novel Vaccine, is described as a preventive strategy that will confer a robust protection against the main life threatening bacterial infections, including multi-resistant strains. PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.
Primary contact

Funding 💰

Total $100K
Select investors Bill & Melinda Gates Foundation
Last update: May 13, 2018